224 related articles for article (PubMed ID: 19903806)
41. [Papillomavirus screening: shall it be performed systematically?].
Agius G; Beby-Defaux A
Transfus Clin Biol; 2003 Apr; 10(2):86-9. PubMed ID: 12763151
[No Abstract] [Full Text] [Related]
42. Forgotten implications of HPV positivity for the majority of females: a clinical perspective.
Tidy J
Cytopathology; 2002 Oct; 13(5):263-6. PubMed ID: 12421441
[No Abstract] [Full Text] [Related]
43. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
44. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
[TBL] [Abstract][Full Text] [Related]
45. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.
Clavel C; Masure M; Bory JP; Putaud I; Mangeonjean C; Lorenzato M; Nazeyrollas P; Gabriel R; Quereux C; Birembaut P
Br J Cancer; 2001 Jun; 84(12):1616-23. PubMed ID: 11401314
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
47. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.
Rodríguez AC; Schiffman M; Herrero R; Wacholder S; Hildesheim A; Castle PE; Solomon D; Burk R;
J Natl Cancer Inst; 2008 Apr; 100(7):513-7. PubMed ID: 18364507
[TBL] [Abstract][Full Text] [Related]
48. Could HPV testing become the sole primary cervical screening test?
Sasieni P; Cuzick J
J Med Screen; 2002; 9(2):49-51. PubMed ID: 12133918
[No Abstract] [Full Text] [Related]
49. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.
Kocken M; Helmerhorst TJ; Berkhof J; Louwers JA; Nobbenhuis MA; Bais AG; Hogewoning CJ; Zaal A; Verheijen RH; Snijders PJ; Meijer CJ
Lancet Oncol; 2011 May; 12(5):441-50. PubMed ID: 21530398
[TBL] [Abstract][Full Text] [Related]
50. Human papillomavirus DNA testing in community screening for diseases of the cervix uteri.
Chan SY
Clin Sci (Lond); 1996 Sep; 91(3):250-2. PubMed ID: 8869401
[No Abstract] [Full Text] [Related]
51. Screening based on papillomavirus detection: too many false alarms.
Prescrire Int; 2010 Aug; 19(108):178-9. PubMed ID: 20939456
[TBL] [Abstract][Full Text] [Related]
52. [New guidelines for prevention of cervix cancer. ARG report on investigation and treatment of abnormal cytological smears].
Strander B; Elfgren K; Andrae B
Lakartidningen; 2011 Mar 9-15; 108(10):533-5. PubMed ID: 21744553
[No Abstract] [Full Text] [Related]
53. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
54. HPV DNA testing for cervical cancer screening. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
Wright TC
Int J Gynaecol Obstet; 2006 Nov; 95 Suppl 1():S239-46. PubMed ID: 17161163
[No Abstract] [Full Text] [Related]
55. ASC-US and HPV testing.
Choma KK
Am J Nurs; 2003 Feb; 103(2):42-50; 51 quiz. PubMed ID: 12582337
[No Abstract] [Full Text] [Related]
56. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
[TBL] [Abstract][Full Text] [Related]
57. HPV testing is not useful for LSIL Triage--but stay tuned.
Stoler MH
Adv Anat Pathol; 2001 May; 8(3):160-4. PubMed ID: 11345239
[No Abstract] [Full Text] [Related]
58. Atypical squamous cells of undetermined significance in liquid-based cytologic specimens: results of reflex human papillomavirus testing and histologic follow-up in routine practice with comparison of interpretive and probabilistic reporting methods.
Levi AW; Kelly DP; Rosenthal DL; Ronnett BM
Cancer; 2003 Aug; 99(4):191-7. PubMed ID: 12925979
[TBL] [Abstract][Full Text] [Related]
59. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
60. Is there a role for human papillomavirus testing in clinical practice?
Kaufman RH
Obstet Gynecol; 2001 Nov; 98(5 Pt 1):724-5. PubMed ID: 11704159
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
